Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10454578 | 0.96 | TSHR (0.44) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL1162364 | 0.92 | TSHR (0.42) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL29152953 | 0.92 | TSHR (0.46) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL8824241 | 0.87 | TSHR (0.50) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL89278 | 0.86 | TSHR (0.41) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| Silicate SCHEMBL11879531 | 0.85 | TSHR (0.38) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL7111318 | 0.85 | TSHR (0.43) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL8824208 | 0.84 | TSHR (0.51) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL1161936 | 0.82 | TSHR (0.42) | TSHRTDP1MAPTCACNA1BAPBA1 | |
| SCHEMBL1368224 | 0.82 | TDP1 (0.39) | TSHRTDP1MAPTCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118338783-A | Composition for controlling arthropods | 宝洁公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20220228067-A1 | SURFACTANT COMPOSITION FOR FOAMING SAND | NOF CORPORATION (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3981525-A1 | SURFACTANT COMPOSITION FOR FOAMING SAND | NOF Corporation (JP) | 2022-04-13 | — | — | EP | disclosed |
| US-11197807-B2 | Gel-type oil-in-water emulsion composition | FUJIFILM CORPORATION (JP) | 2021-12-14 | — | — | US | disclosed |
| EP-3613408-B1 | GEL TYPE OIL-IN-WATER EMULSION COMPOSITION | FUJIFILM CORP (JP) | 2021-02-24 | — | — | EP | disclosed |
| EP-3613408-A1 | OIL-IN-WATER EMULSION COMPOSITION GEL | FUJIFILM Corporation (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20200046615-A1 | GEL-TYPE OIL-IN-WATER EMULSION COMPOSITION | FUJIFILM CORPORATION (JP) | 2020-02-13 | — | — | US | disclosed |
| US-8901072-B2 | Glycopeptide and lipoglycopeptide antibiotics with improved solubility | THE MEDICINES COMPANY (US) | 2014-12-02 | — | — | US | disclosed |
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011019839-A2 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | THE MEDICINES COMPANY (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149632-A1 | GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS WITH IMPROVED SOLUBILITY | NGLY1, LGALS3BP, GYPA | TSHR 3204/4885TDP1 3648/4885MAPT 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.